LBPO.BCS01 · 生物信息与计算 · Late-Breaking
头颈癌的空间分析揭示两种具有不同上皮-间质转化模式的生态系统
Spatial analysis of head and neck cancer reveals two ecosystems with distinct modes of epithelial-to-mesenchymal transition
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:单细胞RNA测序揭示了头颈部鳞状细胞癌(HNSCC)中多样化的恶性程序,包括部分上皮-间质转化(p-EMT)——一种与侵袭和不良结局相关的状态。然而,p-EMT在肿瘤内如何进行空间组织,以及如何受肿瘤微环境(TME)塑造,仍不明确。在此,我们使用空间转录组学来界定HPV阳性和HPV阴性HNSCC中p-EMT的全肿瘤空间构架,并识别其微环境驱动因素。
方法:我们使用10x Visium空间转录组学对26例原发性HNSCC肿瘤(18例HPV阴性,8例HPV阳性)进行分析,其中11例肿瘤配有配对的单细胞RNA测序。细胞状态通过共识表达元程序(meta-programs)来定义,恶性区域则通过推断的拷贝数畸变来识别。空间相互作用采用基于距离的邻域分析进行量化,恶性区域被分层为肿瘤边缘和核心区室。关键发现通过在配对切片上进行高分辨率Visium HD、在40例喉鳞状细胞癌独立队列中进行25重CODEX空间蛋白质组学,以及体外细胞因子扰动实验加以验证。
结果:HPV阳性肿瘤表现出更高的细胞密度、免疫富集的微环境以及与缺氧一致的恶性程序,同时p-EMT相对匮乏。相比之下,HPV阴性肿瘤表现出显著的p-EMT,且分离为两种不同的空间构架。经典的p-EMT边缘模式定位于侵袭前沿,在此处p-EMT恶性细胞通过TGFbeta相关信号与成纤维细胞发生空间偶联。值得注意的是,我们识别出一种替代性的p-EMT核心构架,其特征为p-EMT在整个肿瘤核心弥漫分布,并与免疫抑制性巨噬细胞和中性粒细胞共定位。这一与空间生态位相关的转录程序在大型外部队列中与更差的总生存相关。配体-受体分析和体外验证提示制瘤素M(OSM)是肿瘤核心中p-EMT的关键上游驱动因素。Visium HD和CODEX均独立证实了p-EMT状态的空间组织及相应的TME相互作用。值得注意的是,两种p-EMT构架在同一肿瘤的多个样本间保持一致,表明其为全肿瘤范围的组织状态,而非区域特异性的变异。
结论:我们在HNSCC中识别出两种由不同微环境程序驱动的全肿瘤p-EMT构架:肿瘤边缘的成纤维细胞来源TGFbeta和肿瘤核心的髓系来源OSM。这些发现确立了OSM作为p-EMT的一种新型调控因子,并提示空间组织化的EMT程序是肿瘤侵袭性在临床上相关的决定因素,可能对多种癌症类型具有意义。
查看英文原文 English abstract
Background: Single-cell RNA sequencing has revealed diverse malignant programs in head and neck squamous cell carcinoma (HNSCC), including partial epithelial-to-mesenchymal transition (p-EMT), a state linked to invasion and poor outcome. However, how p-EMT is spatially organized within tumors and shaped by the tumor microenvironment (TME) remains unclear. Here, we used spatial transcriptomics to define tumor-wide spatial architectures of p-EMT in HPV-positive and HPV-negative HNSCC and to identify their microenvironmental drivers.
Methods: We profiled 26 primary HNSCC tumors (18 HPV-negative, 8 HPV-positive) using 10x Visium spatial transcriptomics, with paired single-cell RNA-seq for 11 tumors. Cell states were defined using consensus expression meta-programs, and malignant regions were identified via inferred copy number aberrations. Spatial interactions were quantified using distance-based neighborhood analyses, and malignant regions were stratified into tumor edge and core compartments. Key findings were validated using high-resolution Visium HD on paired sections, 25-plex CODEX spatial proteomics in an independent cohort of 40 laryngeal squamous cell carcinomas, and cytokine perturbation assays in vitro .
Results: HPV-positive tumors exhibited increased cellular density, an immune-enriched microenvironment, and malignant programs consistent with hypoxia, alongside relative depletion of p-EMT. In contrast, HPV-negative tumors showed prominent p-EMT that segregated into two distinct spatial architectures. The canonical p-EMT edge pattern localized to the invasive front, where p-EMT malignant cells spatially coupled to fibroblasts through TGFbeta-associated signaling. Notably, we identified an alternative p-EMT core architecture characterized by diffuse p-EMT throughout tumor cores and co-localization with immunosuppressive macrophages and neutrophils. This spatial niche-related transcriptional program was associated with worse overall survival in large external cohorts. Ligand-receptor analyses and in vitro validations implicated oncostatin M (OSM) as a key upstream driver of p-EMT in tumor cores. Both Visium HD and CODEX independently confirmed the spatial organization of p-EMT states and the corresponding TME interactions. Notably, both p-EMT architectures were consistent across multiple samples from the same tumor, indicating tumor-wide organizational states rather than region-specific variability.
Conclusions: We identify two tumor-wide p-EMT architectures in HNSCC driven by distinct microenvironmental programs: fibroblast-derived TGFbeta at tumor edges and myeloid-derived OSM in tumor cores. These findings establish OSM as a novel regulator of p-EMT and suggest spatially organized EMT programs as clinically relevant determinants of tumor aggressiveness, with potential implications across cancer types.
利益披露 Disclosure
D. Simkin, None..
T. F. Barrett, None..
L. Zhang, None..
M. J. Moore, None..
A. R. Greenwald, None..
N. G. Darnell, None..
M. Mints, None..
S. Ramadan, None..
V. Yu, None..
R. D. Mullins, None..
J. Zaretsky, None..
P. Bischoff, None..
D. Adkins, None..
W. L. Thorstad, None..
S. D. Karam, None..
R. C. Paniello, None..
J. T. Rich, None..
R. S. Jackson, None..
P. Pipkorn, None..
P. A. Zolkind, None..
G. Peng, None..
R. A. Harbison, None..
R. Chernock, None..
A. S. Parikh, None..
S. V. Puram, None.
I. Tirosh,
Immunitas Therapeutics Independent Contractor.